PDGFR and cKIT Gastrointestinal Stromal Tumors Test sale cost 3000 AED
Molecular Karyotyping for Amniotic Fluid Test sale cost 3740 AED Molecular Karyotyping for Amniotic Fluid Test Cost 4,160 د.إ Original price was: 4,160 د.إ.3,740 د.إCurrent price is: 3,740 د.إ.
Duchenne Becker Muscular Dystrophy DMD BMD Gene Mutation Test sale cost 3280 AED Duchenne Becker Muscular Dystrophy DMD BMD Gene Mutation Test Cost 3,640 د.إ Original price was: 3,640 د.إ.3,280 د.إCurrent price is: 3,280 د.إ.
Sale!

PDGFR and cKIT Gastrointestinal Stromal Tumors Test Cost

Original price was: 4,000 د.إ.Current price is: 3,000 د.إ.

-25%

The PDGFR and cKIT Gastrointestinal Stromal Tumors (GIST) Test is a specialized diagnostic assessment available at DNA Labs UAE. This test is designed to identify mutations in the PDGFRA and KIT genes, which are known to play a significant role in the development of gastrointestinal stromal tumors. GISTs are a rare group of cancers affecting the digestive tract or nearby structures within the abdomen. The presence of specific mutations in these genes can influence treatment decisions and prognostic outcomes for patients.

DNA Labs UAE, a leading facility in genetic and molecular diagnostics, offers this test for 3,000 AED. The test involves analyzing a sample of the tumor tissue to detect mutations in the PDGFRA and KIT genes. Results from this test can help healthcare providers tailor treatment strategies more effectively, opting for targeted therapies that can significantly improve patient outcomes. The PDGFR and cKIT Gastrointestinal Stromal Tumors Test is a crucial tool in the personalized medicine approach for managing GISTs, providing insights that can lead to more effective and individualized treatment plans.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

PDGFR and cKIT Gastrointestinal Stromal Tumors Test

At DNA Labs UAE, we offer the PDGFR and cKIT Gastrointestinal Stromal Tumors Test to help diagnose and manage gastrointestinal stromal tumors (GISTs). This test is available for a cost of 3000.0 AED.

Test Details

The PDGFR and cKIT Gastrointestinal Stromal Tumors Test focuses on the analysis of paraffin embedded tissue blocks. It utilizes Sanger Sequencing, a method commonly used in genetics testing, to identify any mutations in the PDGFR and cKIT genes. These genes are receptor tyrosine kinases that are crucial for cell development and function.

Pre Test Information

In order to undergo the PDGFR and cKIT Gastrointestinal Stromal Tumors Test, a doctor’s prescription is required. However, please note that this test is not applicable for individuals who are planning surgery, are pregnant, or have plans to travel abroad.

Test Process and Report Delivery

Once the tumor tissue sample is obtained, the test will be performed, and the report will be delivered within 7-8 days.

Role of PDGFR and cKIT in GISTs

Gastrointestinal stromal tumors (GISTs) are a type of cancer that originates in the gastrointestinal tract. Mutations in the PDGFR and cKIT genes are commonly found in GISTs. In normal cells, these genes help regulate cell growth, division, and survival. However, when mutations occur, the receptors become overactive, leading to uncontrolled cell proliferation and tumor formation.

Treatment Options

Targeting PDGFR and cKIT has proven to be an effective therapeutic strategy for GISTs. Imatinib mesylate (Gleevec) is a tyrosine kinase inhibitor that specifically targets both PDGFR and cKIT. By inhibiting the activity of these receptors, imatinib can block the signaling pathways that promote tumor growth and survival. Imatinib has revolutionized the treatment of GISTs and is considered the standard first-line therapy for advanced or metastatic disease.

However, it is important to note that not all GISTs respond to imatinib, and resistance to the drug can develop over time. In such cases, other targeted therapies, such as sunitinib or regorafenib, may be used to overcome resistance and further inhibit the activity of PDGFR and cKIT.

Ongoing Research

Research in the field of GISTs is ongoing, with a focus on developing new therapies and strategies to overcome resistance and improve outcomes for patients. The discovery of PDGFR and cKIT as key drivers of GISTs has paved the way for targeted treatments and has significantly impacted the management of this disease.

In conclusion, the PDGFR and cKIT Gastrointestinal Stromal Tumors Test offered by DNA Labs UAE is an essential tool for the diagnosis and management of GISTs. By identifying mutations in these genes, doctors can determine the most appropriate treatment options for patients, including the use of targeted therapies such as imatinib. This test plays a crucial role in improving patient outcomes and advancing research in the field of GISTs.

Test Name PDGFR and cKIT Gastrointestinal Stromal Tumors Test
Components Paraffin embedded tissue blocks
Price 3000.0 AED
Sample Condition Tumor tissue
Report Delivery 7-8 days
Method Sanger Sequencing
Test type Genetics
Doctor Gynecologist
Test Department:
Pre Test Information PDGFR + cKIT (Gastrointestinal Stromal Tumors) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details

PDGFR and cKIT are both receptor tyrosine kinases that play a critical role in the development and function of cells. Mutations in these genes have been found to be common in gastrointestinal stromal tumors (GISTs), a type of cancer that originates in the gastrointestinal tract.

In normal cells, PDGFR and cKIT help regulate cell growth, division, and survival. However, when mutations occur in these genes, the receptors become constitutively activated, leading to uncontrolled cell proliferation and tumor formation.

Targeting PDGFR and cKIT has proven to be an effective therapeutic strategy for GISTs. Imatinib mesylate (Gleevec) is a tyrosine kinase inhibitor that specifically targets both PDGFR and cKIT. By inhibiting the activity of these receptors, imatinib can block the signaling pathways that promote tumor growth and survival.

Imatinib has revolutionized the treatment of GISTs and has become the standard first-line therapy for patients with advanced or metastatic disease. However, not all GISTs respond to imatinib, and resistance to the drug can develop over time. In such cases, other targeted therapies, such as sunitinib or regorafenib, may be used to overcome resistance and further inhibit the activity of PDGFR and cKIT.

In conclusion, PDGFR and cKIT are key drivers of gastrointestinal stromal tumors, and targeting these receptors with tyrosine kinase inhibitors has revolutionized the treatment of GISTs. Ongoing research is focused on developing new therapies and strategies to overcome resistance and improve outcomes for patients with this disease.

SKU: TEST-4704 Category:

Related products